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Coagulase-negative staphylococci (CoNS) are the main pathogens causing hospital-acquired external-ventricular-drain-
(EVD-) and lumbar-drain- (LD-) associated meningitis and ventriculitis. The treatment of these infections can be challenging
and may require combination of intraventricular and intravenous administration of antibiotics. Limited animal data demonstrate
rapid daptomycin bactericidal activity, adequate penetration in the setting of inﬂamed meninges, and extended half-life in the
ventricles Steenbergen et al. (2009). There are limited clinical data using daptomycin intravenously and/or intraventricularly for
the treatment of central nervous system infections (CNS) Elvy et al. (2008), Stucki et al. (2007), Lee et al. (2008) and Wallace et al.
(2009). We report here our experience in the treatment of an EVD-related infection.
1.CaseReport
A 52-year-old female with history of hypertension, smoking,
alcohol dependence, and coronary vascular disease with re-
cent myocardial infarction was admitted due to acute change
inmentalstatus.Thepatienthadaspontaneousintraventric-
ularhemorrhage,andanemergencybedsideventriculostomy
wasperformed.Herhospitalcoursewasmarkedbypersistent
fevers in spite of multiple negative blood, cerebrospinal
ﬂuid (CSF), and urinary cultures. She received empiric levo-
ﬂoxacin intravenously 750mg daily and vancomycin 1 gram
intravenously every 12 hours until day 9 of hospitalization.
Herneurologicfunctionsteadilyimproved,andtheventricu-
lostomy was discontinued on day 11. However, her CSF cul-
tures on that day yielded coagulase-negative staphylococcal
(CoNS) species. Vancomycin 1 gram and rifampin 600mg
intravenously were administered every 12 hours. On day 15,
computerized tomography (CT) of the head demonstrated
increased intraventricular hemorrhage requiring reinsertion
of an external ventriculostomy. Repeated CSF analysis de-
monstrated elevated WBC (57cells/mm3 and protein
149mg/dL) with decreased glucose (67mg/dL). CSF cultures
yielded CoNS again. Cultures of CSF continued to yield
CoNS for the next three days despite the addition of dapto-
mycin intravenously at 10mg/kg (dosed at actual body
weight) daily. As a result, intraventricular daptomycin was
added on day 18, 10mg daily for the ﬁrst two days and then
every other day. Culture of CSF became sterile on day 25
following 7 days of daptomycin intravenous and intraven-
tricular therapy in addition to continued administration of
intravenous vancomycin and rifampin. The second ventri-
culostomy was discontinued on day 38 (as was rifampin ad-
ministration). Intravenous daptomycin and vancomycin
were discontinued on day 55 after 37 days of dual treatment.
Mental status progressively improved during this time.
Daptomycin peak and trough levels in the CSF were
measured on day 29, and day 30, respectively (correlating
to day 10 following the start of intravenous and day 112 Case Reports in Medicine
followingthestartofintraventriculardaptomycin).Thepeak
CSF level (following intravenous and intraventricular ad-
ministration) was 6.30mcg/mL on day 29 and the trough
CSF level was 1.39mcg/mL on day 30. The serum trough
level on day 30 was 20.15mcg/mL, and the minimum in-
hibitory concentration (MIC) of CoNS to daptomycin was
<1mcg/mL.
The remaining hospital course was complicated with re-
spiratoryfailurerequiringtracheostomyandventilationsup-
port, ventilator-associated pneumonia, sacral pressure ulcer,
and Clostridium diﬃcile colitis. The patient was successfully
discharged on day 65 to a rehabilitation center.
2. Discussion
Data in animal models support rapid bactericidal activity
of daptomycin. Early studies of MRSA ventriculitis in ani-
mals demonstrate daptomycin achieving greater bactericidal
activity, more rapid killing kinetics, longer intraventricular
half-life than vancomycin, minimal cell wall lysis, and signif-
icant reduction in host inﬂammatory reaction and cortical
injury [1]. Several clinical reports describe successful use of
daptomycinforthetreatmentofvariousCNSinfections(e.g.,
meningitis, septic brain emboli, EVD-associated ventriculi-
tis, etc.) caused by gram-positive bacteria (e.g., methicillin-
resistantStaphylococcusaureus,Enterococcusfaecalis,et c.)[2–
5]. Doses of daptomycin used ranged from 6 to 12mk/kg
for intravenous administration and 5 to 10mg every other
day for intraventricular administration. Daptomycin was
chosen either due to failure or adverse events of standard
antibiotics early on in the course of the infection. Recent
pharmacokinetic studyofasingleintravenous10mg/kgdose
in patients with indwelling external CSF shunts menin-
gitis/ventriculitis demonstrated CSF penetration of 11.5%
(corrected for protein binding) [6].
In our patient, the addition of intravenous daptomycin
was precipitated by persistent growth of CoNS in spite of
treatment with vancomycin and rifampin. The decision to
addintraventricularadministrationofdaptomycinwasmade
due to continued neurosurgical need for the ventriculostomy
and potential limited CSF penetration of intravenous dap-
tomycin. We found trough CSF levels of daptomycin to be
2-fold greater than the MIC for CoNS with peak levels well
over 6-fold greater. These levels were obtained in the setting
of both intravenous and intraventricular administration of
daptomycin, and we cannot comment on the penetration
and/or eﬃcacy of intravenous daptomycin alone in this
setting (or the need to add intraventricular daptomycin rou-
tinely). The impact of synergy between rifampin and dap-
tomycin was not quantitated in our patient, and we do not
believe continued use of vancomycin provided additional
beneﬁt in this case. Our patient’s outcome was similarly
successful as previous CNS infections treated with dapto-
mycin.
We feel more clinical data are needed to delineate con-
sistent daptomycin CSF penetration and role for intraven-
tricular administration of daptomycin in CNS infections in
conjunction with removal of involved prosthetic devices.
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